$4.610
-0.173 (-3.76%)Al cierre
Rentabilidad y márgenes de TTNP
Evaluating the bottom line, Titan Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -82.74%, provide a clear picture of how effectively TTNP converts its operational activities into shareholder value.
Comparativa sectorial de TTNP
In the context of the broader market, TTNP competes directly with industry leaders such as CPHI and PTIX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TTNP's gross margin of N/A stands against CPHI's 8.81% and PTIX's N/A. Such benchmarking helps identify whether Titan Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.